Table 2.
Clinical and pathologic characteristics of the study cohort.
| Median (Range) | n = 1501 (100%) | |
|---|---|---|
| Clinical Characteristics | ||
| Age at diagnosis, years | 54 (23–89) | - |
| BMI at diagnosis, kg/m2 | 26.1 (16.5–59.0) | - |
| Pathologic Characteristics | ||
| Invasive tumor size*, cm | 1.5 (0.01–10.5) | - |
| Breast Surgery | ||
| Lumpectomy | - | 927 (62%) |
| Mastectomy | - | 574 (38%) |
| Axillary Surgery | ||
| None | - | 178 (12%) |
| SLNB | - | 928 (62%) |
| ALND | - | 395 (26%) |
| #LN’s removed, SLNB | 2 (1–13) | - |
| #LN’s removed, ALND | 16 (3–43) | - |
| # Positive LN’s, ALND | 2 (0–39) | - |
| Radiation Therapy | ||
| None | - | 402 (27%) |
| Partial breast (PBI) | - | 92 (6%) |
| Whole breast/ chest wall only (B/CW) | - | 698 (47%) |
| B/CW + SC | - | 194 (13%) |
| B/CW + SC +PAB | - | 115 (8%) |
| Neoadjuvant Chemotherapy | ||
| Yes | - | 151 (10%) |
| No | - | 1350 (90%) |
| Adjuvant Chemotherapy | ||
| Yes | - | 571 (38%) |
| No | - | 930 (62%) |
| Hormonal Therapy | ||
| Yes | - | 1110 (74%) |
| No | - | 391 (26%) |
Abbreviations: BMI = Body Mass Index, ALND = Axillary lymph node dissection, SLNB = Sentinel lymph node biopsy, LN = lymph node, SC= Supraclavicular, PAB = Posterior Axillary Boost
*
Excludes tumor size for patients who underwent neoadjuvant chemotherapy